Stelara 90 MG/ML syringeml
Ended Awarded
- Contract number
- SPE2DR26FCEZ1
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $16,584
Award facts
- Contract value 100% obligated
- $16,584.13 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency has issued a delivery order valued at $16,584.13 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Stelara 90 mg/mL syringes. The delivery order, awarded on November 12, 2025, with an ultimate completion date of December 4, 2025, is structured as a firm fixed-price contract with no set-aside designation, indicating DMS Pharmaceutical Group competed successfully in an unrestricted procurement. This delivery order is issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the Defense Logistics Agency, designated as SPE2DR under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative.
The PPV-G GEN V program represents a $30.3 billion acquisition strategy under which the Defense Logistics Agency establishes multiple regional prime vendor contractors to supply a comprehensive range of pharmaceutical products and medical consumables to Department of Defense healthcare facilities worldwide. DMS Pharmaceutical Group's IDC, awarded on November 13, 2025, carries a ceiling value of $499,999,999 and extends through December 31, 2036, with a 30-month base period followed by three 30-month option periods. Stelara, an immunosuppressant biologic agent, exemplifies the specialty pharmaceutical products within DMS Pharmaceutical Group's established portfolio, which also includes oncology treatments, vaccines, and emergency medications critical to military medical operations globally.
Quick answers
Who was awarded contract SPE2DR26FCEZ1?
SPE2DR26FCEZ1 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on November 12, 2025.
How much is contract SPE2DR26FCEZ1 worth?
The government has obligated $16,584 on SPE2DR26FCEZ1.
Is contract SPE2DR26FCEZ1 an order under another contract?
Yes. SPE2DR26FCEZ1 is a delivery order under SPE2DR25D9130, an indefinite delivery contract.
Was contract SPE2DR26FCEZ1 competed?
The extent of competition for SPE2DR26FCEZ1 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award